Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia

Gordois, A., Scuffham, P., Warren, E. et al. (1 more author) (2003) Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. British Journal of Cancer, 89. 634 - 640. ISSN 0007-0920

Abstract

Metadata

Authors/Creators:
  • Gordois, A.
  • Scuffham, P.
  • Warren, E.
  • Ward, S.
Copyright, Publisher and Additional Information: © 2003 Cancer Research UK. Reproduced in accordance with the publisher's self-archiving policy. This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
Keywords: chemotherapy; cost-effectiveness; economic evaluation; Glivec; Chronic Myelogenous Leukemia; ABL Tyrosine Kinase; Conventional Chemotherapy; Philadelphia-Chromosone; Cytogenertic Response; Interferon-alpha; Blast crisis; Transplantation; Inhibitor; Survival
Dates:
  • Published: 12 August 2003
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 15 Oct 2015 15:08
Last Modified: 15 Oct 2015 15:08
Published Version: https://doi.org/10.1038/sj.bjc.6601151
Status: Published
Publisher: Cancer Research UK
Refereed: Yes
Identification Number: https://doi.org/10.1038/sj.bjc.6601151

Download

Filename: Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia..pdf

Share / Export

Statistics